From RAS Biochemistry to Drug Design: How Mutant Cycling & GTP Thresholds Inform Next-Generation RAS Inhibitors
- Revisiting the core biochemistry of RAS mutants to understand how cellular GTP loading and signaling thresholds drive oncogenic transformation
- Examining what first-generation covalent and non-covalent inhibitors revealed about mutant-specific cycling behavior and switch-II pocket accessibility
- Applying biochemical insights from early KRAS inhibitor successes and limitations to guide the design of next-generation RAS-targeted therapies